MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, TTRX had $4,203,545 increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$4,203,545
Unit: Dollar
Positive Cash Flow Breakdown
    • Proceeds from issuance of stock,...
    • Accounts payable and accrued exp...
    • Amortization of deferred offerin...
    • Others
Negative Cash Flow Breakdown
    • Net gain from change in fair val...
    • Gain from change in fair value o...
    • Purchases of intangible assets

Cash Flow
2025-12-31
Net loss attributable to common stockholders
-3,194,080
Depreciation and amortization
52,746
Stock-based compensation expense
419,245
Non-cash operating lease expense
1,172
Common stock issued in exchange for services
250,000
Net gain from change in fair value of derivative liability instrument
2,574,971
Gain from change in fair value of forward contract liability
-380,442
Amortization of deferred offering cost
496,948
Prepaid expenses and other current assets
-105,025
Accounts payable and accrued expenses
2,261,456
Net cash used in operating activities
-2,562,901
Purchases of intangible assets
152,986
Net cash used in investing activities
-152,986
Proceeds from issuance of stock, net of issuance costs
6,919,432
Net cash provided by financing activities
6,919,432
Net increase (decrease) in cash and cash equivalents
4,203,545
Cash and cash equivalents at beginning of year
872,599
Cash and cash equivalents at end of year
5,076,144
Unit: Dollar.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofstock, net of issuance...$6,919,432 Net cash provided byfinancing activities$6,919,432 Net increase(decrease) in cash and cash...$4,203,545 Canceled cashflow$2,715,887 Accounts payable andaccrued expenses$2,261,456 Amortization of deferredoffering cost$496,948 Stock-based compensationexpense$419,245 Common stock issued inexchange for services$250,000 Prepaid expenses andother current assets-$105,025 Depreciation andamortization$52,746 Non-cash operating leaseexpense$1,172 Net cash used inoperating activities-$2,562,901 Net cash used ininvesting activities-$152,986 Canceled cashflow$3,586,592 Net lossattributable to common...-$3,194,080 Purchases of intangibleassets$152,986 Net gain from changein fair value of...$2,574,971 Gain from change infair value of forward...-$380,442

Turn Therapeutics Inc. (TTRX)

Turn Therapeutics Inc. (TTRX)